Abstract 1482P
Background
More than 80% patients of Carcinoma Gall bladder (Ca GB) present with unresectable or disseminated disease. In these patients jaundice can be very distressing leading to poor quality of life (QOL) PTBD has been advocated to palliate this but, its impact on QOL has not been adequately studied.
Methods
Prospective observational study over two years included patients of proven unresectable/disseminated Ca GB presenting with jaundice. Pre-procedure parameters were recorded and PTBD done. Quality of Life (QOL) was assessed by EORTC QLQ-C30 and BIL-21 scores prior to the treatment and after 1- month. Post procedure complications were reported. Follow up was done at 1,3 and 6 months.
Results
Study included 43 patients of unresectable/disseminated Ca GB. Median age was 52 years with 74% females. 26 patients underwent unilateral (U/L) and 17 bilateral (B/L) PTBD. 4 patients needed B/L PTBD for inadequate bilirubin fall at 4 weeks. Mean serum bilirubin was 18.3 ± 7.3 mg/dl, albumin was 2.9 ± 0.5 mg/dl and INR was 1.7 ± 1.2. Commonest indication for PTBD was pruritus (65%) and only 12% patients had cholangitis. Bilirubin level at 1 week and 1 month was 15mg/dl and 7.1 mg/dl respectively(p=0.0002). Unfortunately, EORTC QLQ-C30 QOL scores showed decline in all aspects at 1 months and 3 months. Even in BIL-21 scores although there was improvement in Jaundice scale those with anxiety, pain and side effects had decline. Most patients had morbidity related to either slippage of PTBD or peri-tubal leakage. Also, inevitability of disease progression due to lack of treatment caused significant anxiety. 4 patients expired within 30 days due to cholangitis. Survival at 1-, 3- and 6- months was 60%, 23% and 7% respectively with median survival of 38 days.
Conclusions
Although jaundice is a fairly debilitating symptom in patients with unresectable Ca GB, palliation in form of PTBD may not always lead to improvement of QOL. Psychological counselling and proper guidance in terms of care of drains as well proper pain management is imperative to provide these terminally ill patients with best supportive care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
S. Galodha.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10